» Articles » PMID: 32384593

Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD

Overview
Journal Nutrients
Date 2020 May 10
PMID 32384593
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease in industrialized countries. It is regarded as the hepatic manifestation of the metabolic syndrome (MetS) resulting from insulin resistance. Moreover, insulin resistance impairs glycogen synthesis, postprandially diverting a substantial amount of carbohydrates to the liver and storing them there as fat. NAFLD has far-reaching metabolic consequences involving glucose and lipoprotein metabolism disorders and risk of cardiovascular disease, the leading cause of death worldwide. No pharmaceutical options are currently approved for the treatment of NAFLD. Exercise training and dietary interventions remain the cornerstone of NAFLD treatment. Current international guidelines state that the primary goal of nutritional therapy is to reduce energy intake to achieve a 7%-10% reduction in body weight. Meal replacement therapy (formula diets) results in more pronounced weight loss compared to conventional calorie-restricted diets. However, studies have shown that body mass index (BMI) or weight reduction is not obligatory for decreasing hepatic fat content or to restore normal liver function. Recent studies have achieved significant reductions in liver fat with eucaloric diets and without weight loss through macronutrient modifications. Based on this evidence, an integrative nutritional therapeutic concept was formulated that combines the most effective nutrition approaches termed "liver-fasting." It involves the temporary use of a low calorie diet (total meal replacement with a specific high-protein, high-soluble fiber, lower-carbohydrate formula), followed by stepwise food reintroduction that implements a Mediterranean style low-carb diet as basic nutrition.

Citing Articles

Carabrone Attenuates Metabolic Dysfunction-Associated Steatohepatitis by Targeting STAT3 in Mice.

Pan A, Jin J, Wu Y, Zhang Q, Chen H, Hu Y MedComm (2020). 2025; 6(3):e70145.

PMID: 40066227 PMC: 11892021. DOI: 10.1002/mco2.70145.


MAFLD: Exploring the Systemic Effects Beyond Liver.

Dayal U, Soni U, Bansal S, Aggarwal K, Chennupati C, Kanagala S J Community Hosp Intern Med Perspect. 2025; 15(1):42-48.

PMID: 39867144 PMC: 11759081. DOI: 10.55729/2000-9666.1426.


Body shape index (ABSI), body roundness index (BRI) and risk factors of metabolic syndrome among overweight and obese adults: a cross-sectional study.

Fahami M, Hojati A, Farhangi M BMC Endocr Disord. 2024; 24(1):230.

PMID: 39468529 PMC: 11514815. DOI: 10.1186/s12902-024-01763-6.


Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress.

Minetti E, Hamburg N, Matsui R Front Cardiovasc Med. 2024; 11:1469492.

PMID: 39411175 PMC: 11473390. DOI: 10.3389/fcvm.2024.1469492.


Efficacy of the Mediterranean Diet Containing Different Macronutrients on Non-Alcoholic Fatty Liver Disease.

Ulucay Kestane V, Bas M Nutrients. 2024; 16(16).

PMID: 39203835 PMC: 11357554. DOI: 10.3390/nu16162699.


References
1.
Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y . Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol Res Pract. 2016; 2016:1459790. PMC: 5019889. DOI: 10.1155/2016/1459790. View

2.
Shulman G . Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371(12):1131-41. DOI: 10.1056/NEJMra1011035. View

3.
Petersen K, Dufour S, Savage D, Bilz S, Solomon G, Yonemitsu S . The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007; 104(31):12587-94. PMC: 1924794. DOI: 10.1073/pnas.0705408104. View

4.
Rehackova L, Araujo-Soares V, Adamson A, Steven S, Taylor R, Sniehotta F . Acceptability of a very-low-energy diet in Type 2 diabetes: patient experiences and behaviour regulation. Diabet Med. 2017; 34(11):1554-1567. PMC: 5656912. DOI: 10.1111/dme.13426. View

5.
Taylor R . Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013; 36(4):1047-55. PMC: 3609491. DOI: 10.2337/dc12-1805. View